E Introducing The "Medicinal Mushroom" Stock Index

TM Editors' Note: This article discusses one or more penny stocks and/or microcaps. Such stocks are easily manipulated; do your own careful due diligence. Keep in mind that percentage increases/decreases in penny stocks cannot be readily compared with larger stocks.

The enormous potential of medicines based on edible (functional) mushrooms and magic (psychedelic) mushrooms to treat depression, anxiety and addiction health issues has some whispering that psychedelics are the next billion dollar industry given that Big Pharma has largely walked away from mental health research.  As such, the playing field is wide open for smaller biopharmaceutical companies to become actively involved in the research, development and introduction of such products. To track the growth - and price performance - of those companies in the sector munKNEE.com has created The Medicinal Mushroom Stock Index to complement its Pure-Play Pot Stock Index. The 12 constituents in the index are highlighted below.

According to Statista the mental health services sector in the U.S. is a $225 billion per year market and psychedelic drugs have the potential to provide effective treatment options for mental health disorders that afflict more than 1 billion people.

A 2018 report by the Lancet Commission estimates that mental health disorders will cost the global economy $16 trillion between now and 2030 in lost productivity so, with so much at stake, there is plenty of room in the marketplace for both functional mushrooms to improve brain function and mental health (the functional (edible) mushrooms market is estimated to be a $23.3 billion market that will have a very solid 8.04% CAGR from now through 2025) along with psychedelic drugs to treat mental health disorders.

1. Compass Pathways (CMPS)

CMPS is the early industry darling in the psychedelics space given that its psilocybin-based therapy for treatment-resistant depression is in Phase 2 of clinical trials and it has received Breakthrough Therapy Designation for its research from the Food and Drug Administration (FDA).

2. MindMed (MMEDF)

Several other psychedelics companies have capitalized on the increased attention on psychedelic stocks with MindMed receiving the most attention as it has three drug initiatives already in Phase 2 with several other initiatives in Phase 1 trials including one with the University Hospital Basel’s Liechti Lab that combines MDMA and LSD.

1 2 3 4
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
William K. 4 weeks ago Member's comment

Certainly this will be an interesting narrow focused portfolio to watch.